
Study shows low rates of T-cell malignancies following CAR-T
A new study has demonstrated that the frequency of second primary malignancies (SPMs) is no higher with CAR-T cell therapies than with previous standard-of-care strategies. The authors found that T cell malignancies represented a small minority of adverse events at just 1.5%. The paper ‘… Read More














